Quantcast

Latest Thalidomide Stories

2010-06-05 16:30:00

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable patients who had not been previously...

2010-06-04 14:00:00

EMERYVILLE, Calif., June 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by...

76a0f1da7f9039905c6459fc0ec92e91
2010-05-01 08:35:34

Norwegian researchers say that pregnant women are three times more likely to suffer from severe morning sickness if their mothers did. About 2 percent of women suffer from excessive nausea and vomiting in pregnancy, which can require hospital treatment. However, a study of 2.3 million births showed threefold higher numbers if mothers had moms that suffered the same condition. Experts said the results might help women better understand their risk. Hyperemesis is an excessive sickness that...

2010-04-01 08:52:00

WASHINGTON, April 1 /PRNewswire-USNewswire/ -- Two years after the Food and Drug Administration Amendments Act of 2007 (FDAAA) gave FDA new powers to require Risk Evaluation and Mitigation Strategies (REMS) for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing...

2010-03-22 07:00:00

WALTHAM, Mass., March 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Multiple Myeloma reveal that market growth will be driven by increased use of...

2009-12-16 07:35:00

Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") (Nasdaq: KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor,...

2009-12-16 07:30:00

NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma...

2009-12-07 14:17:48

Carfilzomib induces a response in 45 percent of patients and reduces neuropathy The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology. The updated data from the 17-site study focuses on patients with relapsed or resistant multiple myeloma who have received one to...

2009-12-07 07:35:00

Response Rate Increases to 41% and Median Overall Survival Reported at 25 Months for All Evaluable Patients QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. ("Keryx") (Nasdaq: KERX) reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine...

2009-12-07 07:30:00

NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 (perifosine) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. Data from the study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (Velcade(R)) in Patients...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.